ミシガン州における食道癌の臨床試験
ミシガン州内の拠点で、食道癌に関する22件の研究が参加者を募集しています。
ミシガン州内の都市
- Grand Rapids14件の研究
- Detroit9件の研究
- Ann Arbor4件の研究
- Lansing3件の研究
- Livonia3件の研究
- Canton3件の研究
- Clinton Township3件の研究
- Warren3件の研究
- Farmington Hills3件の研究
公式研究テキスト（英語）
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- START Midwest Cancer and Hematology Centers of W Michigan, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06465069Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health IHA - Obstetrics and Gynecology West Arbor, Ann Arbor
- 他50件
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2026/10/02更新 · NCT07283939Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- MyMichigan Medical Center Gratiot, Alma
- MyMichigan Medical Center Alpena, Alpena
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor, Ann Arbor
- 他68件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Profound Research -OMG - TriAtria Cancer Center, Farmington Hills
被験者募集中第2相
18歳以上 · 全性別 · 2026/10/02更新 · NCT06760819Pan-tumor MRD Study
- The Cancer & Hematology Centers (CHC), Grand Rapids
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/24更新 · NCT06605404Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- START Midwest, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT06128551A Study of LY4257496 in Participants With Cancer (OMNIRAY)
- Barbara Ann Karmanos Cancer Institute, Detroit
- BAMF Health Inc., Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07114601A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
- Barbara Ann Karmanos Cancer Institute, Detroit
- BAMF Health Inc., Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07213791ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Cancer & Hematology Centers of Western Michigan, Grand Rapids
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/14更新 · NCT05059444Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
- Karmanos Cancer Institiute, Detroit
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/10更新 · NCT06293898Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
- Research Site, Grand Rapids
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT07431281Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)
- The Cancer and Hematology Centers ( Site 8912), Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/03更新 · NCT06445972Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First-Line Locally Advanced Unresectable/Metastatic Gastroesophageal Adenocarcinoma (MK-3475-06C/KEYMAKER-U06)
- The Cancer and Hematology Centers ( Site 6912), Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/02更新 · NCT06469944The Vanguard Study: Testing a New Way to Screen for Cancer
- Henry Ford Cancer Institute-Downriver, Brownstown
- Henry Ford Health Center - Brownstown, Brownstown
- Henry Ford Health Center - Chesterfield, Chesterfield
- 他13件
被験者募集中健康なボランティア歓迎
45歳〜75歳 · 全性別 · 2026/09/02更新 · NCT06995898A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Karmanos Cancer Institute, Detroit
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/11更新 · NCT05592626Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
- University of Michigan Rogel Cancer Center, Ann Arbor
被験者募集中第4相
18歳以上 · 女性 · 2026/07/02更新 · NCT05183126Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
- START Midwest /ID# 248685, Grand Rapids
被験者募集中第1相
18歳以上 · 全性別 · 2026/06/23更新 · NCT05005403Sacituzumab Govitecan in Combination With Capecitabine for Advanced Gastrointestinal Cancers After Progression on Standard Therapy
- Henry Ford Cancer-Detroit, Detroit
被験者募集中第1相
18歳以上 · 全性別 · 2025/12/19更新 · NCT06065371A Study of MT-4561 in Patients With Various Advanced Solid Tumors
- START Midwest, Grand Rapids
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/12/11更新 · NCT06943521SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Ann Arbor
- Massive Bio SYNERGY-AI site, Lansing
被験者募集中観察研究
全年齢 · 全性別 · 2025/10/28更新 · NCT0345277464Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
- BAMF Health, Inc., Grand Rapids
被験者募集中第1/2相
15歳以上 · 全性別 · 2025/08/12更新 · NCT06298916A Beta-only IL-2 ImmunoTherapY Study
- Karmanos Cancer Institute, Detroit
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/07/09更新 · NCT05086692ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。